<DOC>
	<DOC>NCT01956097</DOC>
	<brief_summary>The objectives of the current study are to evaluate the efficacy and safety of HX106 in healthy adults with subjective memory complaints for improving neurocognitive functions and to find the changes of brain using magnetic resonance imaging and their associations with the neurocognitive function enhancement.</brief_summary>
	<brief_title>Effects of HX106 on Improvement in Cognitive-Bio-Markers of Memory Function</brief_title>
	<detailed_description />
	<criteria>Age between 20 and 60 years old, Global Deterioration Scale score (GDS) of 2 One or more symptoms of subjective memory impairment High school or higher levels of education. Current pregnancy or breastfeeding Evidence of neurologic or medical conditions Axis I diagnosis when assessed by the board certified psychiatrist using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorder, 4th edition (DSMIV)(SCIDIV), One or more major depressive episode during last 12 months Minimental status examination score of 24 or less Clinical Dementia Rating score of 0.5 or more suggesting cognitive impairment beyond selfperceived subjective deficits Intelligence quotient less than 80 Any history of head trauma involving loss of consciousness or seizure Contraindications to magnetic resonance imaging (MRI) Use of psychotropics in last 3 months Use of oral contraceptive medication Participation in other clinical trials during the study period that might affect the outcome of the present study.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>